2. Signaling Pathways
  3. GPCR/G Protein
    Immunology/Inflammation
  4. CXCR
  5. CXCR Inhibitor

CXCR Inhibitor

CXCR Isoform Comparison

CXCR Inhibitors (55):

Cat. No. Product Name Effect Purity
  • HY-15319
    AMG 487
    		Inhibitor 99.80%
    AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC50s of 8.0 and 8.2 nM, respectively.
  • HY-15251
    Reparixin
    		Inhibitor 99.99%
    Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC50s of 1 and 100 nM, respectively.
  • HY-P4109A
    vMIP-II (1-21) TFA
    		Inhibitor
    vMIP-II (1-21) (NT21MP) TFA is an inhibitor of CXCR4. vMIP-II (1-21) TFA interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) TFA inhibits CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM).
  • HY-N0011
    Baohuoside I
    		Inhibitor 99.96%
    Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of CXCR4, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.
  • HY-119339
    SX-682
    		Inhibitor 99.67%
    SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity.
  • HY-12488
    LY2510924
    		Inhibitor 99.73%
    LY2510924 is a potent and selective CXCR4 antagonist that blocks SDF-1 binding to CXCR4 with an IC50 of 0.079 nM.
  • HY-15252
    Reparixin L-lysine salt
    		Inhibitor 99.66%
    Reparixin L-lysine salt is an allosteric inhibitor of chemokine receptor 1/2 (CXCR1/2) activation.
  • HY-P99190
    Eldelumab
    		Inhibitor
    Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease.
  • HY-101022
    CXCR2-IN-1
    		Inhibitor 99.54%
    CXCR2-IN-1 is a central nervous system penetrant CXCR2 antagonist with a pIC50 of 9.3.
  • HY-P7061A
    ALX 40-4C Trifluoroacetate
    		Inhibitor
    ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a Ki of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC50 of 2.9 μM.
  • HY-P99404
    Quetmolimab
    		Inhibitor
    Quetmolimab is a humanized anti-CX3CL1 monoclonal antibody. However, CX3CL1 is a chemokine with a modulating effect on chemotaxis and adhesion.
  • HY-163475
    CXCL-CXCR1/2-IN-1
    		Inhibitor 99.64%
    CXCL-CXCR1/2-IN-1 is an orally active ELR+CXCL-CXCR1/2 pathway inhibitor with an EC50 of 42.7 nM for CXCR2. CXCL-CXCR1/2-IN-1 shows anticancer and antiangiogenic effects.
  • HY-P10552
    pCXCL8-1aa
    		Inhibitor 98.13%
    pCXCL8-1aa is an anti-inflammatory peptide. pCXCL8-1aa competitively inhibits the binding of CXCL8 to glycosaminoglycans such as heparin sulfate (HS) by binding with high affinity. This reduces the presentation of CXCL8 on the surface of vascular endothelial cells, thereby inhibiting neutrophil migration and inflammatory responses. pCXCL8-1aa can be used to study inflammatory diseases such as rheumatoid arthritis.
  • HY-149096
    CCR7 antagonist 1
    		Inhibitor 99.55%
    CCR7 antagonist 1 (30c) is a dual CXCR2 (IC50 of 11.02 μM) and CCR7 (IC50 of 0.43 μM) antagonist.
  • HY-N3255
    Minecoside
    		Inhibitor 99.86%
    Minecoside is a CXCR4/STAT3 inhibitor with anticancer and anti-inflammatory activity. Minecoside decreases CXCR4 expression and suppresses STAT3 activation, thus to inhibit CXCL 12-induced invasion. Minecoside potently inhibits cancer metastasis and promotes apoptotic progression.
  • HY-P7061
    ALX 40-4C
    		Inhibitor
    ALX 40-4C is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a Ki of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC50 of 2.9 μM.
  • HY-RS03407
    Cxcr4 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cxcr4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-RS03400
    CXCR2 Human Pre-designed siRNA Set A
    		Inhibitor

    CXCR2 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-160041A
    Olaptesed pegol sodium
    		Inhibitor
    Olaptesed pegol sodium A pegylated-based L-oligoribonucleotide aptamer targeting CXCL12. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment.
  • HY-RS03401
    Cxcr2 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cxcr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.